OBJECTIVE: Cross-cultural ethical conflicts are common. However, little is known about how and to what extent acculturation changes
attitudes toward end-of-life care and advance care planning. We compared attitudes toward end-of-life care among Japanese
Americans and Japanese in Japan.
DESIGN: Self-administered questionnaire in English and Japanese.
SETTING AND PARTICIPANTS: Community-based samples of Japanese Americans in Los Angeles and Japanese in Nagoya, Japan: 539 English-speaking Japanese
Americans (EJA), 340 Japanese-speaking Japanese Americans (JJA), and 304 Japanese living in Japan (JJ).
MEASUREMENTS AND MAIN RESULTS: Few subjects (6% to 11%) had discussed end-of-life issues with physicians, while many (EJA, 40%; JJA, 55%; JJ, 54%) desired
to do so. Most preferred group surrogate decision making (EJA, 75%; JJA, 57%; JJ, 69%). After adjustment for demographics
and health status, desire for informing the patient of a terminal prognosis using words increased significantly with acculturation
(EJA, odds ratio [OR] 8.85; 95% confidence interval, [95% CI] 5.4 to 14.3; JJA, OR 2.8; 95% CI 1.8 to 4.4; JJ, OR 1.0). EJA
had more-positive attitudes toward forgoing care, advance care planning, and autonomous decision making.
CONCLUSION: Preference for disclosure, willingness to forgo care, and views of advance care planning shift toward western values as Japanese
Americans acculturate. However, the desire for group decision making is preserved. Recognition of the variability and acculturation
gradient of end-of-life attitudes among Japanese Americans may facilitate decision making and minimize conflicts. Group decision
making should be an option for Japanese Americans.
Key words cross-cultural comparison - acculturation - terminal care - advance directives - decision making
Presented at the annual meeting of the Society of General Internal Medicine, April 29, 1999, San Francisco, Calif.
This study was supported in part by a grant from the VA/UCLA/RAND Medical Treatment Effectiveness Program (MEDTEP) Center
for Asians and Pacific Islanders that was funded by Agency for Health Care Policy Research (P50HS07370). Additional project
support was provided by Pfizer Foundation Grants to Support Joint International Research Projects in Japan.